Elodie Persyn

Aug 20, 2024 | medrxiv.org | Carles A. Foguet |Xilin Jiang |Scott Ritchie |Elodie Persyn

A.S.B. reports institutional grants from AstraZeneca, Bayer, Biogen, BioMarin, Bioverativ, Novartis, Regeneron and Sanofi. J.D. serves on scientific advisory boards for AstraZeneca, Novartis, Our Future Health and UK Biobank, and has received multiple grants from academic, charitable and industry sources outside of the submitted work.

Mar 29, 2023 | nature.com | Yu Xu |Scott Ritchie |Maik Pietzner |Loïc Lannelongue |Samuel A. Lambert |Sebastian May-Wilson | +17 more

AbstractThe use of omic modalities to dissect the molecular underpinnings of common diseases and traits is becoming increasingly common. But multi-omic traits can be genetically predicted, which enables highly cost-effective and powerful analyses for studies that do not have multi-omics1.